dc.contributor.author | Kokwaro, GO | |
dc.contributor.author | Indalo, Anne A | |
dc.date.accessioned | 2013-05-31T11:35:26Z | |
dc.date.available | 2013-05-31T11:35:26Z | |
dc.date.issued | 1996-08 | |
dc.identifier.citation | Afr J Health Sci. 1996 Aug;3(3):105-8. | en |
dc.identifier.uri | http://profiles.uonbi.ac.ke/aindalo/publications/kokwaro-go-indalo-aaoxamniquine-inhibits-metabolism-caffeine-hexobarbitone-and- | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/17451311 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/28319 | |
dc.description.abstract | Inhibition of hepatic metabolism of caffeine (as assessed from expiration of (14)CO(2) resulting from N-demethylation of (14)C-labelled caffeine), hexobarbitone (as assessed from sleeping times) and antipyrine (as assessed from expiration of I4CO2 resulting from the oxidation of "C-labelled antipyrine) was studied in male GB-1 mice administered a single SO mg kg-1 oral dose of the schistosomicidal drug oxamniquine. Metabolism of caffeine, catalysed by cytochrome P-4S0 1A2(CYP1A2), was inhibited most, while hexobarbitone and antipyrine metabolism were inhibited to a lesser, though significant, degree. These results indicate a need for further studies to investigate possible clinically relevant inhibition of hepatic drug metabolism by oxamniquine | en |
dc.language.iso | en | en |
dc.publisher | University of Nairobi. | en |
dc.title | Oxamniquine inhibits metabolism of caffeine, hexobarbitone and antipyrine in vivo in mice | en |
dc.type | Article | en |
local.publisher | Department of Pharmaceutics and Pharmacy Practice, Faculty of Pharmacy, University of Nairobi | en |